Powerful cocktail shows promise against bone marrow cancer
NCT ID NCT02969837
First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This phase 2 trial tested a combination of four drugs—elotuzumab, carfilzomib, lenalidomide, and dexamethasone—in 46 people newly diagnosed with multiple myeloma. The goal was to see how many patients achieved a very deep response (stringent complete response or minimal residual disease negativity). The study found that the combination led to high response rates, suggesting it could be a strong initial treatment option.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
elotuzumab, carfilzomib, lenalidomide, dexamethasone
What this could lead to
If successful, this combination could become a powerful first-line treatment for multiple myeloma, potentially leading to deeper remissions and longer survival.
What could go wrong
This is a small, single-arm phase 2 study with no comparison group, so results may not hold up in larger trials. Side effects from the drug combination can be serious.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for MULTIPLE MYELOMA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
NorthShore University Health System
Evanston, Illinois, 60201, United States
-
University of Chicago
Chicago, Illinois, 60637, United States
-
University of Michigan Comprehensive Cancer Center
Ann Arbor, Michigan, 48109, United States